|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Govindan R, Page N, Morgensztern D, Read
W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing
epidemiology of small-cell lung cancer in the United States over
the last 30 years: Analysis of the surveillance, epidemiologic, and
end results database. J Clin Oncol. 24:4539–4544. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dómine M, Moran T, Isla D, Martí JL,
Sullivan I, Provencio M, Olmedo ME, Ponce S, Blasco A and Cobo M:
SEOM clinical guidelines for the treatment of small-cell lung
cancer (SCLC) (2019). Clin Transl Oncol. 22:245–255.
2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dingemans AC, Früh M, Ardizzoni A, Besse
B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N,
Rudin CM, et al: Small-cell lung cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
32:839–853. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
NCCN Guidelines®-Small cell
lung cancer. version 2.2024. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
Accepted at April 12, 2024.
|
|
7
|
Takada M, Fukuoka M, Kawahara M, Sugiura
T, Yokoyama A, Yokota S, Nishiwaki Y, Watanabe K, Noda K, Tamura T,
et al: Phase III study of concurrent versus sequential thoracic
radiotherapy in combination with cisplatin and etoposide for
limited-stage small-cell lung cancer: Results of the Japan clinical
oncology group study 9104. J Clin Oncol. 20:3054–3060.
2002.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Broglio KR and Berry DA: Detecting an
overall survival benefit that is derived from progression-free
survival. J Natl Cancer Inst. 101:1642–1649. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Soria JC, Massard C and Le Chevalier T:
Should progression-free survival be the primary measure of efficacy
for advanced NSCLC therapy? Ann Oncol. 21:2324–2332.
2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Reck M, von Pawel J, Zatloukal P, Ramlau
R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and
Manegold C: Phase III trial of cisplatin plus gemcitabine with
either placebo or bevacizumab ss first-line therapy for nonsquamous
non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hotta K, Kiura K, Fujiwara Y, Takigawa N,
Hisamoto A, Ichihara E, Tabata M and Tanimoto M: Role of survival
post-progression in phase III trials of systemic chemotherapy in
advanced non-small-cell lung cancer: A systematic review. PLoS One.
6(e26646)2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hayashi H, Okamoto I, Morita S, Taguri M
and Nakagawa K: Postprogression survival for first-line
chemotherapy of patients with advanced non-small-cell lung cancer.
Ann Oncol. 23:1537–1541. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Imai H, Takahashi T, Mori K, Ono A,
Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, et
al: Individual-level data on the relationships of progression-free
survival, post-progression survival, and tumor response with
overall survival in patients with advanced non-squamous non-small
cell lung cancer. Neoplasma. 61:233–240. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Imai H, Yamada Y, Sugiyama T, Minemura H,
Kaira K, Kanazawa K, Kasai T, Kaburagi T and Minato K:
Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group. Clinical impact of
post-progression survival on overall survival in elderly patients
with non-small-cell lung cancer harboring sensitive EGFR mutations
treated with first-line EGFR tyrosine kinase inhibitors.
Chemotherapy. 63:181–189. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Imai H, Kishikawa T, Minemura H, Yamada Y,
Ibe T, Mori K, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, et al:
Post-progression survival influences overall survival among
patients with advanced non-small cell lung cancer undergoing
first-line Pembrolizumab monotherapy. Oncology. 99:562–570.
2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kasahara N, Imai H, Kaira K, Mori K,
Wakuda K, Ono A, Taira T, Kenmotsu H, Harada H, Naito T, et al:
Clinical impact of post-progression survival on overall survival in
patients with limited-stage disease small cell lung cancer after
first-line chemoradiotherapy. Radiol Oncol. 49:409–415.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L:
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions. The
IASLC lung cancer staging project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer (version 1.1).
45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Weir CJ and Walley RJ: Statistical
evaluation of biomarkers as surrogate endpoints: A literature
review. Stat Med. 25:183–203. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Fleischer F, Gaschler-Markefski B and
Bluhmki E: A statistical model for the dependence between
progression-free survival and overall survival. Stat Med.
28:2669–2686. 2009.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Foster NR, Qi Y, Shi Q, Krook JE, Kugler
JW, Jett JR, Molina JR, Schild SE, Adjei AA and Mandrekar SJ: Tumor
response and progression-free survival as potential surrogate
endpoints for overall survival in extensive stage small-cell lung
cancer: Findings on the basis of North central cancer treatment
group trials. Cancer. 117:1262–1271. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Foster NR, Renfro LA, Schild SE, Redman
MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS,
Gandara DR, et al: Multitrial evaluation of progression-free
survival as a surrogate end point for overall survival in
first-line extensive-stage small-cell lung cancer. J Thorac Oncol.
10:1099–1106. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Imai H, Mori K, Wakuda K, Ono A, Akamatsu
H, Shukuya T, Taira T, Kenmotsu H, Naito T, Kaira K, et al:
Progression-free survival, post-progression survival, and tumor
response as surrogate markers for overall survival in patients with
extensive small cell lung cancer. Ann Thorac Med. 10:61–66.
2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Imai H, Mori K, Watase N, Fujimoto S,
Kaira K, Yamada M and Minato K: Clinical significance of the
relationship between progression-free survival or postprogression
survival and overall survival in patients with extensive
disease-small-cell lung cancer treated with carboplatin plus
etoposide. Can Respir J. 2016(5405810)2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Imai H, Kaira K and Minato K: Clinical
significance of post-progression survival in lung cancer. Thorac
Cancer. 8:379–386. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kagohashi K, Satoh H, Ishikawa H, Ohtsuka
M and Sekizawa K: Liver metastasis at the time of initial diagnosis
of lung cancer. Med Oncol. 20:25–28. 2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang X, Wang Z, Pan J, Lu ZY, Xu D, Zhang
HJ, Wang SH, Huang DY and Chen XF: Patterns of extrathoracic
metastases in different histological types of lung cancer. Front
Oncol. 10(715)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Riihimäki M, Hemminki A, Fallah M, Thomsen
H, Sundquist K, Sundquist J and Hemminki K: Metastatic sites and
survival in lung cancer. Lung Cancer. 86:78–84. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Arriola E, Trigo JM, Sánchez-Gastaldo A,
Navarro A, Perez C, Crama L and Ponce-Aix S: Prognostic value of
clinical staging according to TNM in patients with SCLC: A
real-world surveillance epidemiology and end-results database
analysis. JTO Clin Res Rep. 3(100266)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nakazawa K, Kurishima K, Tamura T,
Kagohashi K, Ishikawa H, Satoh H and Hizawa N: Specific organ
metastases and survival in small cell lung cancer. Oncol Lett.
4:617–620. 2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang S, Wang Y, Li S, Liu Y and Cheng Y:
A retrospective analysis of prognostic factors and treatment
choices in small cell lung cancer with liver metastasis. J Thorac
Dis. 15:6776–6787. 2023.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ross HJ, Hu C, Higgins KA, Jabbour SK,
Kozono DE, Owonikoko TK, Movsas B, Solberg T, Xiao C, Williams TM,
et al: NRG Oncology/Alliance LU005: A phase II/III randomized
clinical trial of chemoradiation versus chemoradiation plus
atezolizumab in limited stage small cell lung cancer. J Clin Oncol.
38(TPS9082)2020.
|
|
33
|
Senan S, Okamoto I, Lee GW, Chen Y, Niho
S, Mak G, Yao W, Shire N, Jiang H and Cho BC: Design and rationale
for a phase III, randomized, placebo-controlled trial of Durvalumab
with or without tremelimumab after concurrent chemoradiotherapy for
patients with limited-stage small-cell lung cancer: The Adriatic
study. Clin Lung Cancer. 21:e84–e88. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Fried DB, Morris DE, Poole C, Rosenman JG,
Halle JS, Detterbeck FC, Hensing TA and Socinski MA: Systematic
review evaluating the timing of thoracic radiation therapy in
combined modality therapy for limited-stage small-cell lung cancer.
J Clin Oncol. 22:4837–4845. 2004.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Baize N, Monnet I, Greillier L, Geier M,
Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, et
al: Carboplatin plus etoposide versus topotecan as second-line
treatment for patients with sensitive relapsed small-cell lung
cancer: An open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol. 21:1224–1233. 2020.PubMed/NCBI View Article : Google Scholar
|
